Introduction
Materials and Methods
Patients’ selection
Screening for high-probability IgG4-TIN
Criterion | The Mayo Clinic criteria | JSN criteria |
---|---|---|
Histology | Plasma cell-rich TIN with >10 IgG4+ plasma cells/HPF field in the most concentrated field (mandatory criterion) | a. Dense lymphoplasmacytic infiltrate with >10 IgG4+ plasma cells/HPF and/or IgG4/IgG+ plasma cell ratio of >40 % |
TBM immune complex deposits by immunofluorescence, immunohistochemistry, and/or electron microscopy | b. Characteristic storiform fibrosis | |
Imaging | Small peripheral low-attenuation cortical nodules, round or wedge-shapped lesions, or diffuse patchy involvement | Multiple low-density lesions on enhanced CT, diffuse kidney enlargement, hypovascular solitary nodule, hypertrophic lesion of the renal pelvic wall |
Serology | Elevated serum IgG4 or total IgG level | Elevated serum IgG4 or total IgG level |
Clinical features | None | Clinical or laboratory evidence of kidney damage |
Other organ involvement | Characteristic findings of IgG4-RD in other organs | Characteristic findings of IgG4-RD in other organs |
Definite IgG4-TIN | The histologic feature and at least one other feature from imaging, serology or other organ involvement | The histologic feature (a and b) and at least two of other features from imaging, serology or other organ involvement |
Confirmation of IgG4-TIN
Statistical analysis
Results
Cases of suspected IgG4-TIN
Cases of high-probability IgG4-TIN
High-probability IgG4-TIN (n = 12) | Excluded (n = 43) | P value | |
---|---|---|---|
Female gender (n (%)) | 6 (50 ) | 26 (60 ) | 0.152 |
Age (y) | 52 (30–76) | 37 (14–63) | 0.003 |
Proteinuria (0.01-0.15 g/24 h) | 1.04 (0.21 - 2.69) | 3.12 (0.06 - 17.33) | 0.043 |
Albumin (35–55 g/L) | 32.8 (25.7 - 42.1) | 31.8 (15–46) | 0.682 |
Serum creatinine (44–132 μmol/L) | 311.7 (46–953) | 492.8 (105–1832) | 0.070 |
eGFR (80-120 ml/min) | 23.6 (5.4 - 65.3) | 29.5 (3.2 - 143.1) | 0.405 |
Pt No. | Age/Gender | Clinical Diagnosis | Proteinuria (0.01-0.15g/24h) | Hematuria | ALB (35-55 g/L) | SCr (44-132μmol/L) | eGFR (80-120ml/min) | Serum IgG (751-1560mg/dL) | Serum C3 (79-152 mg/dL) | Principal Pathological Diagnosis | IgG4 (cells/HPF) | IgG4/IgG (%) | Storiform fibrosis | Stage of Fibrosis | TBM Deposits | Imaging Findings | Other Organ Involvement |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 65 M | ARF | 0.30 | - | 36 | 381 | 13.2 | 1910 | 67 | Idiopathic TIN | 14 | 23.3 | - | 0 | - | Bilateral Enlarged | - |
2 | 42 F | ARF, AAV | 1.41 | 4+ | 35 | 447 | 9.9 | 2370 | 78 | Pauci-immune CreGN | 22 | 56.7 | - | 0 | + | - | - |
3 | 52 F | SLE, CRF | 1.57 | 2+ | 30 | 273 | 15.5 | 3050 | 86 | LN | 11 | 84.6 | - | 1 | + | - | PF |
4 | 76 M | CGN, CRF | 1.41 | 4+ | 33 | 380 | 11.9 | 1990 | 75 | Immune complex CreGN | 10 | 43.5 | - | 1 | - | - | PF |
5 | 62 M | CGN, CRF | 1.17 | - | 30 | 234 | 25.6 | 4050 | 45 | Idiopathic TIN | 55 | 93.2 | + | 2 | + | Bilateral Enlarged | PF Lymph node Enlarged |
6 | 49 M | CGN, CRF | 0.40 | 3+ | 37.6 | 138 | 52 | 1050 | 81 | IgAN | 12 | 32.2 | - | 1 | + | - | PF |
7 | 33 F | ARF | 0.21 | - | 39.9 | 231 | 24.9 | 2010 | 123 | Drug-induced TIN | 22 | 58 | - | 1 | + | - | - |
8 | 59 M | ARF | 0.60 | 3+ | 26.6 | 1108 | 10.7 | 1380 | 86 | Anti-GBM CreGN | 29 | 60.3 | - | 1 | - | - | PF |
9 | 36 F | CGN, CRF | 2.69 | 3+ | 30.4 | 199 | 40.7 | 1910 | 121 | IgAN | 14 | 40.3 | - | 2 | + | - | - |
10 | 56 F | ARF, AAV | 1.58 | 3+ | 26.9 | 1832 | 5.4 | 2120 | 80 | Crescentic IgAN | 20 | 95 | + | 1 | + | - | PF |
11 | 59 M | ARF | 0.49 | - | 25.7 | 586 | 8.4 | 1860 | 106 | Immune complex CreGN | 52 | 91 | + | 2 | + | Bilateral Enlarged | - |
12 | 30 F | CGN,CKD2 | 0.61 | - | 42.1 | 105 | 65.3 | 1870 | 109 | IgAN | 25 | 63.7 | - | 2 | + | - | - |
Abundant plasma cells samples | High-probability IgG4-TIN | |||||
---|---|---|---|---|---|---|
Pathological features | High-probability IgG4-TIN (n = 12) | Excluded (n = 43) | P value 1 | Confirmed IgG4-TIN (n = 2) | Unconfirmed IgG4-TIN (n = 10) | P Value 2 |
Inflammation infiltrating renal capsule | 4 (33.3 ) | 11 (25.6) | 0.594 | 1 (50) | 3 (30) | 0.584 |
Inflammation infiltrating renal medulla | 6 (50) | 23 (53.5) | 0.831 | 1 (50) | 5 (50) | 1.000 |
Isolated fibrosis | 6 (50) | 3 (7) | 0.000 | 2 (100) | 4 (40) | 0.121 |
Collagenous fibrosis | 8 (66.7) | 7 (16.3) | 0.001 | 2 (100) | 6 (60) | 0.273 |
Storiform fibrosis | 3 (25) | 1 (2.3) | 0.007 | 2 (100) | 1 (10) | 0.007 |
Lymphoid follicles | 2 (16.7) | 1 (2.3) | 0.053 | 0 (0) | 2 (20) | 0.488 |
Granulomatous lesions | 1 (8.3) | 0 (0) | 0.056 | 0 (0) | 1 (10) | 0.640 |
Necrotizing angiitis | 1 (8.3) | 1 (2.3) | 0.326 | 0 (0) | 1 (10) | 0.640 |
Obliterative phlebitis | 0 (0) | 0 (0) | -- | 0 (0) | 0 (0) | -- |
Eosinophil infiltration | 8 (66.7) | 18 (41.9) | 0.128 | 2 (100) | 6 (60) | 0.273 |
Neutrophil infiltration | 6 (50) | 14 (32.6) | 0.267 | 1 (50) | 5 (50) | 1.000 |
Tubulitis | 9 (75) | 16 (37.2) | 0.020 | 2 (100) | 7 (70) | 0.371 |
Peritubular capillaritis | 3 (25) | 13 (30.2) | 0.724 | 1 (50) | 2 (20) | 0.371 |
Tubular necrosis | 8 (66.7) | 18 (41.9) | 0.128 | 0 (0) | 8 (80) | 0.091 |
TBM immune complex deposits | 9 (75) | 12 (27.9) | 0.006 | 2 (100) | 7 (70) | 0.371 |